JMP Securities analyst Jason Butler reiterated a Buy rating on Morphosys Ag (NASDAQ:MOR) on Monday, setting a price target of $41, which is approximately 337.10% above the present share price of $9.38.
Butler expects Morphosys Ag to post earnings per share (EPS) of -$3.30 for the fourth quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Morphosys Ag, with an average price target of $90.61.
The analysts price targets range from a high of $140.22 to a low of $41.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $41.24 million and a net profit of -$82.36 million. The company's market cap is $1.28 billion.
According to TipRanks.com, JMP Securities analyst Jason Butler is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 0.5% and a 40.45% success rate.
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery (NASDAQ:DISCA) segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.